The clinical implications of the systemic inflammatory reaction related to cardiac operations in children

Cardiology in the Young

Volumn 13, Issue 3, 2003, Pages 228-239

  Seghaye, Marie Christine ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMIODARONE; APROTININ; ASCORBIC ACID; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CIMETIDINE; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5B; COMPLEMENT COMPONENT C6; COMPLEMENT COMPONENT C9; CORTICOSTEROID; DEXAMETHASONE; FREE RADICAL; GLUCOCORTICOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOCORTIN 1; NITROPRUSSIDE SODIUM; PHOSPHODIESTERASE INHIBITOR; RANITIDINE; TROPONIN T; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CAPILLARY LEAK SYNDROME; CARDIOPULMONARY BYPASS; CELL INTERACTION; CHILD; CLINICAL FEATURE; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CYTOKINE PRODUCTION; DEGRANULATION; DISEASE CONTROL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GENETIC PREDISPOSITION; HEART ARRHYTHMIA; HOMEOSTASIS; HUMAN; LEUKOCYTE ACTIVATION; MORBIDITY; MULTIPLE ORGAN FAILURE; NONHUMAN; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE THROMBOSIS; PROTEIN FUNCTION; RECEPTOR BLOCKING; REPERFUSION INJURY; RISK ASSESSMENT; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; VASCULAR ENDOTHELIUM;

CAPILLARY LEAK SYNDROME; CARDIAC SURGICAL PROCEDURES; COMPLEMENT SYSTEM PROTEINS; CYTOKINES; ENDOTHELIUM, VASCULAR; GLUCOCORTICOIDS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; NF-KAPPA B; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 26444462456     PISSN: 10479511     EISSN: 14671107     Source Type: Journal    
DOI: 10.1017/S1047951103000465     Document Type: Article

References (79)

1. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990; 265: 621-636.
2. Smith EM, Cadet P, Stefano GB, Opp MR, Hughes TK Jr. IL-10 as a mediator in the HPA axis and brain. J Neuroimmunol 1999; 100: 140-148.
3. Weiler JM. Introduction. In: Whaley K, Loos M, Weiler JM (eds). Complement in health and disease, 2nd edn. Kluwer Academic Publishers, Dordrecht, Boston, London, 1993, pp 1-37.
4. Takabayashi T, Vannier E, Clark BD, et al. A new biologic role for C3a and C3a desArg: Regulation of TNF-alpha and IL-1 beta synthesis. J Immunol. 1996; 156: 3455-3460.
5. Ertel W, Morrison MH, Ayala A, Chaudry IH. Hypoxemia in the absence of blood loss or significant hypotension causes inflammatory cytokine release. Am J Physiol 1995; 269: R160-R166.
6. Barnes PJ, Karin M. Nuclear factor-kappaB: A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066-1071.
7. Dinarello CA. Proinflammatory cytokines. Chest 2000; 118: 503-508.
8. Elenkov IJ, Chrousos GP. Stress hormones, proinflammatory and antiinflammatory cytokines, and autoimmunity. Ann N Y Acad Sci 2002; 966: 290-303.
9. Meldrum DR. Tumor necrosis factor in the heart. Am J Physiol 1998; 274: R577-R595.
10. Luheshi GN, Stefferl A, Turnbull AV, et al. Febrile response to tissue inflammation involves both peripheral and brain IL-1 and TNF-alpha in the rat. Am J Physiol 1997; 272: R862-R868.
11. Heuertz RM, Webster RO. Role of C-reactive protein in acute lung injury. Mol Med Today 1997; 3: 539-545.
12. Tilg H, Dinarello CA, Mier JW. IL-6 and APPs: Anti-inflammatory and immunosuppressive mediators. Immunol Today 1997; 18: 428-432.
13. Cassatella MA, Meda L, Gasperini S, Calzetti F, Bonora S. Interleukin 10 (IL-10) upregulates IL-1 receptor antagonist production from lipopolysaccharide-stimulated human polymorphonuclear leukocytes by delaying mRNA degradation. J Exp Med 1994; 179: 1695-1699.
14. Rennick D, Berg D, Holland G. Interleukin 10: An overview. Prog Growth Factor Res 1992; 4: 207-227.
15. Albelda SM, Smith CW, Ward PA. Adhesion molecules and inflammatory injury. Faseb J 1994; 8: 504-512.
16. Adams DH, Shaw S. Leucocyte-endothelial interactions and regulation of leucocyte migration. Lancet 1994; 343: 831-836.
17. Leist M, Nicotera P. The shape of cell death. Biochem Biophys Res Commun 1997; 236: 1-9.
18. Steller H. Mechanisms and genes of cellular suicide. Science 1995; 267: 1445-1449.
19. Larrick JW, Wright SC. Cytotoxic mechanism of tumor necrosis factor-alpha. Faseb J 1990; 4: 3215-3223.
20. Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest 1993; 103: 565-575.
21. Royall JA, Berkow RL, Beckman JS, Cunningham MK, Matalon S, Freeman BA. Tumor necrosis factor and interleukin 1 alpha increase vascular endothelial permeability. Am J Physiol 1989; 257: L399-L410.
22. Taniguchi T, Koido Y, Aiboshi J, Yamashita T, Suzaki S, Kurokawa A. Change in the ratio of interleukin-6 to interleukin-10 predicts a poor outcome in patients with systemic inflammatory response syndrome. Crit Care Med 1999; 27: 1262-1264.
23. Hövels-Gürich HH, Schumacher K, Vazquez-Jimenez JF, et al. Cytokine balance in infants undergoing cardiac operation. Ann Thorac Surg 2002; 73: 601-608; discussion 608-609.
24. Qing M, Vazquez-Jimenez JF, Klosterhalfen B, et al. Influence of temperature during cardiopulmonary bypass on leukocyte activation, cytokine balance, and post-operative organ damage. Shock 2001; 15: 372-377.
25. Vazquez-Jimenez JF, Qing M, Hermanns B, et al. Moderate hypothermia during cardiopulmonary bypass reduces myocardial cell damage and myocardial cell death related to cardiac surgery. J Am Coll Cardiol 2001; 38: 1216-1223.
26. van Deventer SJ. Cytokine and cytokine receptor polymorphisms in infectious disease. Intensive Care Med 2000; 26: S98-S102.
27. Verthelyi D, Klinman DM. Sex hormone levels correlate with the activity of cytokine-secreting cells in vivo. Immunology 2000; 100: 384-390.
28. Ma Qing, Schumacher K, Heise R, et al. Intramyocardial synthesis of pro- and anti-inflammatory cytokines in infants with congenital cardiac defects. J Am Coll Cardiol (in press).
29. Ferreiro CR, Chagas AC, Carvalho MH, et al. Influence of hypoxia on nitric oxide synthase activity and gene expression in children with congenital heart disease: A novel pathophysiological adaptive mechanism. Circulation 2001; 103: 2272-2276.
30. Tabardel Y, Duchateau J, Schmartz D, et al. Corticosteroids increase blood interleukin-10 levels during cardiopulmonary bypass in men. Surgery 1996; 119: 76-80.
31. Suberville S, Bellocq A, Fouqueray B, et al. Regulation of interleukin-10 production by beta-adrenergic agonists. Eur J Immunol 1996; 26: 2601-2605.
32. Corbel M, Germain N, Lanchou J, et al. The selective phosphodiesterase 4 inhibitor RP 73-401 reduced matrix metalloproteinase 9 activity and transforming growth factor-beta release during acute lung injury in mice: The role of the balance between Tumor necrosis factor-alpha and interleukin-10. J Pharmacol Exp Ther 2002; 301: 258-265.
33. Wolk K, Docke W, von Baehr V, Volk H, Sabat R. Comparison of monocyte functions after LPS- or IL-10-induced reorientation: Importance in clinical immunoparalysis. Pathobiology 1999; 67: 253-256.
34. Adib-Conquy M, Asehnoune K, Moine P, Cavaillon JM. Long-term-impaired expression of nuclear factor-kappa B and I kappa B alpha in peripheral blood mononuclear cells of trauma patients. J Leukoc Biol 2001; 70: 30-38.
35. Volk HD, Reinke P, Krausch D, et al. Monocyte deactivation - rationale for a new therapeutic strategy in sepsis. Intensive Care Med 1996; 22: S474-S480.
36. Chenoweth DE, Cooper SW, Hugli TE, Stewart RW, Blackstone EH, Kirklin JW. Complement activation during cardiopulmonary bypass: Evidence for generation of C3a and C5a anaphylatoxins. N Engl J Med 1981; 304: 497-503.
37. Kirklin JK, Westaby S, Blackstone EH, Kirklin JW, Chenoweth DE, Pacifico AD. Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1983; 86: 845-857.
38. Hammerschmidt DE, Stroncek DF, Bowers TK, et al. Complement activation and neutropenia occurring during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1981; 81: 370-377.
39. Kirklin JK, Chenoweth DE, Naftel DC, et al. Effects of protamine administration after cardiopulmonary bypass on complement, blood elements, and the hemodynamic state. Ann Thorac Surg 1986; 41: 193-199.
40. Tanaka K, Takao M, Yada I, Yuasa H, Kusagawa M, Deguchi K. Alterations in coagulation and fibrinolysis associated with cardiopulmonary bypass during open heart surgery. J Cardiothorac Anesth 1989; 3: 181-188.
41. Fung M, Loubser PG, Undar A, et al. Inhibition of complement, neutrophil, and platelet activation by an anti-factor D monoclonal antibody in simulated cardiopulmonary bypass circuits. J Thorac Cardiovasc Surg 2001; 122: 113-122.
42. Meri S, Aronen M, Leijala M. Complement activation during cardiopulmonary bypass in children. Complement 1988; 5: 46-54.
43. Seghave MC, Duchateau J, Grabitz RG, et al. Complement activation during cardiopulmonary bypass in infants and children. Relation to postoperative multiple system organ failure. J Thorac Cardiovasc Surg 1993; 106: 978-987.
44. Seghaye MC, Duchateau J, Grabitz RG, et al. Complement, leukocytes, and leukocyte elastase in full-term neonates undergoing cardiac operation. J Thorac Cardiovasc Surg 1994; 108: 29-36.
45. Vaage J, Valen G. Pathophysiology and mediators of ischemia-reperfusion injury with special reference to cardiac surgery. A review. Scand J Thorac Cardiovasc Surg Suppl 1993; 41: 1-18.
46. Tassani P, Barankay A, Haas F, et al. Cardiac surgery with deep hypothermic circulatory arrest produces less systemic inflammatory response than low-flow cardiopulmonary bypass in newborns. J Thorac Cardiovasc SUrg 2002; 123: 648-654.
47. Wilson I, Gillinov AM, Curtis WE, et al. Inhibition of neutrophil adherence improves postischemic ventricular performance of the neonatal heart. Circulation 1993; 88: II372-II319.
48. Seghaye MC, Duchateau J, Grabitz RG, et al. Histamine liberation related to cardiopulmonary bypass in children: Possible relation to transient postoperative arrhythmias. J Thorac Cardiovasc Surg 1996; 111: 971-981.
49. McBride WT, Armstrong MA, Gilliland H, McMurray TJ. The balance of pro and anti-inflammatory cytokines in plasma and bronchoalveolar lavage (BAL) at paediatric cardiac surgery. Cytokine 1996; 8: 724-729.
50. Seghaye M, Duchateau J, Bruniaux J, et al. Interleukin-10 release related to cardiopulmonary bypass in infants undergoing cardiac operations. J Thorac Cardiovasc Surg 1996; 111: 545-553.
51. Journois D, Israel-Biet D, Pouard P, et al. High-volume, zero-balanced hemofiltration to reduce delayed inflammatory response to cardiopulmonary bypass in children. Anesthesiology 1996; 85: 965-976.
52. Tarnok A, Hambsch J, Schneider P. Cardiopulmonary bypass-induced increase of serum interleukin-10 levels in children. J Thorac Cardiovasc Surg 1998; 115: 475-477.
53. Jansen NJ, van Oeveren W, Gu YJ, van Vliet MH, Eijsman L, Wildevuur CR. Endotoxin release and tumor necrosis factor formation during cardiopulmonary bypass. Ann Thorac Surg 1992; 54: 744-747; discussion 747-748.
54. Metinko AP, Kunkel SL, Standiford TJ, Strieter RM. Anoxia-hyperoxia induces monocyte-derived interleukin-8. J Clin Invest 1992; 90: 791-798.
55. Gormley SM, McBride WT, Armstrong MA, et al. Plasma and urinary cytokine homeostasis and renal function during cardiac surgery without cardiopulmonary bypass. Cytokine 2002; 17: 61-65.
56. Seghaye MC, Grabitz RG, Duchateau J, et al. Inflammatory reaction and capillary leak syndrome related to cardiopulmonary bypass in neonates undergoing cardiac operations. J Thorac Cardiovasc Surg 1996; 112: 687-697.
57. Simpson J, Stephenson T. Regulation of extracellular fluid volume in neonates. Early Hum Dev 1993; 34: 179-190.
58. Hövels-Gürich HH, Vazquez-Jimenez JF, Silvestri A, et al. Production of proinflammatory cytokines and myocardial dysfunction after arterial switch operation in neonates with transposition of great arteries. J Thorac Cardiovasc Surg 2002; 124: 811-820.
59. Levi R, Zavecz JH. Acceleration of idioventricular rhythms by histamine in guinea pig heart: Mediation by H2 receptors. Circ Res 1979; 44: 847-855.
60. Levi R, Owen DAA, Trzeciakowski J. Actions of Histamine on the heart and vasculature. In: Granellin CR, Parsons ME (eds). Pharmacology of histamine receptors. Wright, PSG, Bristol, London, Boston, 1998, pp 236-297.
61. Grant JW, Serwer GA, Armstrong BE, Oldham HN, Anderson PA. Junctional tachycardia in infants and children after open heart surgery for congenital heart disease. Am J Cardiol 1987; 59: 1216-1218.
62. Martin D, Lown B. Is amiodarone good for heartburn? Arch Intern Med 1990; 150: 1345-1347.
63. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864-874.
64. Kalfin RE, Engelman RM, Rousou JA, et al. Induction of interleukin-8 expression during cardiopulmonary bypass. Circulation 1993; 88: II401-II406.
65. Seghaye MC, Duchateau J, Grabitz RG, et al. Effect of sodium nitroprusside on complement activation induced by cardiopulmonary bypass: A clinical and experimental study. J Thorac Cardiovasc Surg 1996; 111: 882-892.
66. Tassani P, Kunkel R, Richter JA, et al. Effect of C1-esterase-inhibitor on capillary leak and inflammatory response syndrome during arterial switch operations in neonates. J Cardiothorac Vasc Anesth 2001; 15: 469-473.
67. Rioux P. TP-10 (AVANT Immunotherapeutics). Curr Opin Investig Drugs 2001; 2: 364-371.
68. Videm V, Mollnes TE, Fosse E, et al. Heparin-coated cardiopulmonary bypass equipment I. Biocompatibility markers and development of complications in a high-risk population. J Thorac Cardiovasc Surg 1999; 117: 794-802.
69. Miyaji K, Hannan RL, Ojito J, Jacobs JP, White JA, Burke RP. Heparin-coated cardiopulmonary bypass circuits: Clinical effects in pediatric cardiac surgery. J Card Surg 2000; 15: 194-198.
70. Watanabe H, Miyamura H, Hayashi J, et al. The influence of a heparin-coated oxygenator during cardiopulmonary bypass on postoperative lung oxygenation capacity in pediatric patients with congenital heart anomalies. J Card Surg 1996; 11: 396-401.
71. Murkin JM. Cardiopulmonary bypass and the inflammatory response: A role for serine protease inhibitors? J Cardiothorac Vasc Anesth 1997; 11: 19-23; discussion 24-25.
72. Seghaye MC, Duchateau J, Grabitz RG, et al. Influence of low-dose aprotinin on the inflammatory reaction due to cardiopulmonary bypass in children. Ann Thorac Surg 1996; 61: 1205-1211.
73. Sisto T, Paajanen H, Metsa-Ketela T, Harmoinen A, Nordback I, Tarkka M. Pretreatment with antioxidants and allopurinol diminishes cardiac onset events in coronary artery bypass grafting. Ann Thorac Surg 1995; 59: 1519-1523.
74. Andersen LW, Thiis J, Kharazmi A, Rygg I. The role of N-acetylcystein administration on the oxidative response of neutrophils during cardiopulmonary bypass. Perfusion 1995; 10: 21-26.
75. Elliott MJ. Ultrafiltration and modified ultrafiltration in pediatric open heart operations. Ann Thorac Surg 1993; 56: 1518-1522.
76. Bokesch PM, Kapural MB, Mossad EB, et al. Do peritoneal catheters remove pro-inflammatory cytokines after cardiopulmonary bypass in neonates? Ann Thorac Surg 2000; 70: 639-643.
77. Bronicki RA, Backer CL, Baden HP, Mavroudis C, Crawford SE, Green TP. Dexamethasone reduces the inflammatory response to cardiopulmonary bypass in children. Ann Thorac Surg 2000; 69: 1490-1495.
78. Valen G, Yan ZQ, Hansson GK. Nuclear factor kappa B and the heart. J Am Coll Cardiol 2001; 38: 307-314.
79. Wong SC, Fukuchi M, Melnyk P, Rodger I, Giaid A. Induction of cyclooxygenase-2 and activation of nuclear factor-kappa B in myocardium of patients with congestive heart failure. Circulation 1998; 98: 100-103.